Aging and disease

ISOAD Become a Member Search

X

Advanced Search

Table of Content

01 February 2013. VOL 4, ISSUE 2 Previous Issue Next Issue

A Review of Ethical Considerations for Ventricular Assist Device Placement in Older Adults
Courtenay R. Bruce

2013, 4 (2): 100-112

PDF (504KB)
Serum Homocysteine, Dehydroepiandrosterone Sulphate and Lipoprotein (a) in Alzheimer’s Disease and Vascular Dementia
Lopamudra Ray, Vineet Kumar Khemka, Prajna Behera, Kausik Bandyopadhyay, Sandip Pal, Keya Pal, Debasis Basu, Sasanka Chakrabarti

2013, 4 (2): 57-64

PDF (928KB)
The Role of Neuromuscular Changes in Aging and Knee Osteoarthritis on Dynamic Postural Control
Judit Takacs, Mark G. Carpenter, S. Jayne Garland, Michael A. Hunt

2013, 4 (2): 84-99

PDF (501KB)
In vivo Age-related Changes in Cortical, Subcortical Nuclei, and Subventricular Zone: A Diffusion Tensor Imaging Study
Ashok Munivenkatappa, Bhavani Shankara Bagepally, Jitender Saini, Pramod Kumar Pal

2013, 4 (2): 65-75

PDF (871KB)
Large Elastic Artery Stiffness with Aging: Novel Translational Mechanisms and Interventions
Bradley S. Fleenor

2013, 4 (2): 76-83

PDF (429KB)

Cover Illustration

01 February 2013. Vol.4 No.2
Alzheimer’s disease (AD) and vascular dementia (VAD) are the major forms of dementia affecting elderly people, in which the levels of many metabolites are altered in cerebrospinal fluid (CSF) and serum. These metabolites could be risk factors or potential biomarkers, but the significance of some of these are not clearly understood in the context of the disease pathogenesis. In the present study serum levels of homocysteine, dehydroepiandrosterone sulphate (DHEA-S) and lipoprotein (a) or Lp(a) have been measured by ELISA using commercial kits in AD (n = 40), VAD (n = 40) and age matched control subjects (n = 40). The data are compared by ANOVA and post-hoc analysis. The serum homocysteine is markedly elevated compared to control both in AD and VAD subjects, but to a significantly higher extent in the latter. Lp(a) is increased in the serum of VAD subjects only compared to control. Likewise, serum DHEA-S level is lowered in AD but not in VAD compared to control. The analysis of the present data and those published by others suggest that alterations in homocysteine and Lp(a) in serum are indicators of vascular pathology in AD or VAD, while the lowering of serum DHEA-S is a consequence of AD pathology.

[Detail]

Cover Illustration

Alzheimer’s disease (AD) and vascular dementia (VAD) are the major forms of dementia affecting elderly people, in which the levels of many metabolites are altered in cerebrospinal fluid (CSF) and serum. These metabolites could be risk factors or potential biomarkers, but the significance of some of these are not clearly understood in the context of the disease pathogenesis. In the present study serum levels of homocysteine, dehydroepiandrosterone sulphate (DHEA-S) and lipoprotein (a) or Lp(a) have been measured by ELISA using commercial kits in AD (n = 40), VAD (n = 40) and age matched control subjects (n = 40). The data are compared by ANOVA and post-hoc analysis. The serum homocysteine is markedly elevated compared to control both in AD and VAD subjects, but to a significantly higher extent in the latter. Lp(a) is increased in the serum of VAD subjects only compared to control. Likewise, serum DHEA-S level is lowered in AD but not in VAD compared to control. The analysis of the present data and those published by others suggest that alterations in homocysteine and Lp(a) in serum are indicators of vascular pathology in AD or VAD, while the lowering of serum DHEA-S is a consequence of AD pathology.